6 October 2023 - Next year’s Medicare Part B premiums are expected to be announced soon and there is speculation that coverage of another pricey new Alzheimer’s medication could cause monthly costs to go up, echoing what occurred in 2022.

Leqembi received full approval from the FDA in July, becoming the second drug of its kind to hit the market after Aduhelm. The drug comes with an annual cost of $26,500.

Read The Hill article